Therapeutic implications of the prostaglandin pathway in Alzheimer's disease

Biochemical Pharmacology

Volumn 88, Issue 4, 2014, Pages 565-572

  Cudaback, Eiron ^a   Jorstad, Nikolas L ^a   Yang, Yue ^a   Montine, Thomas J ^a   Keene, C Dirk ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Alzheimer's disease; Cyclooxygenase; Neuroinflammation; NSAID; Prostaglandin

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN SYNTHASE; THROMBOXANE;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; FOLLOW UP; GENE EXPRESSION; HUMAN; IMMUNOREGULATION; INFLAMMATION; NERVOUS SYSTEM INFLAMMATION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THERAPY EFFECT;

ALZHEIMER'S DISEASE; CYCLOOXYGENASE; NEUROINFLAMMATION; NSAID; PROSTAGLANDIN;

ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; HUMANS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; SIGNAL TRANSDUCTION;

EID: 84897954152     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.12.014     Document Type: Review

References (132)

1. P.L. McGeer, S. Itagaki, H. Tago, and E.G. McGeer Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR Neurosci Lett 79 1987 195 200 (Pubitemid 17144469)
2. J. Rogers, J. Luber-Narod, S.D. Styren, and W.H. Civin Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease Neurobiol Aging 9 1988 339 349 (Pubitemid 19262065)
3. S. Itagaki, P.L. McGeer, and H. Akiyama Presence of T-cytotoxic suppressor and leucocyte common antigen positive cells in Alzheimer's disease brain tissue Neurosci Lett 91 1988 259 264
4. P. Eikelenboom, C.E. Hack, J.M. Rozemuller, and F.C. Stam Complement activation in amyloid plaques in Alzheimer's dementia Virchows Arch B Cell Pathol Incl Mol Pathol 56 1989 259 262 (Pubitemid 19049180)
5. D.H. Cribbs, N.C. Berchtold, V. Perreau, P.D. Coleman, J. Rogers, and A.J. Tenner et al. Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study J Neuroinflammation 9 2012 179
6. H. Bruunsgaard, and B.K. Pedersen Age-related inflammatory cytokines and disease Immunol Allergy Clin North Am 23 2003 15 39 (Pubitemid 36268302)
7. M.E. Starr, B.M. Evers, and H. Saito Age-associated increase in cytokine production during systemic inflammation: adipose tissue as a major source of IL-6 J Gerontol A Biol Sci Med Sci 64 2009 723 730
8. P. Casolini, A. Catalani, A.R. Zuena, and L. Angelucci Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat J Neurosci Res 68 2002 337 343 (Pubitemid 34462539)
9. A.A. Simen, K.A. Bordner, M.P. Martin, L.A. Moy, and L.C. Barry Cognitive dysfunction with aging and the role of inflammation Ther Adv Chronic Dis 2 2011 175 195
10. C. Holmes, C. Cunningham, E. Zotova, J. Woolford, C. Dean, and S. Kerr et al. Systemic inflammation and disease progression in Alzheimer disease Neurology 73 2009 768 774
11. J.M. Noble, J.J. Manly, N. Schupf, M.X. Tang, R. Mayeux, and J.A. Luchsinger Association of C-reactive protein with cognitive impairment Arch Neurol 67 2010 87 92
12. J. Cooper-Knock, J. Kirby, L. Ferraiuolo, P.R. Heath, M. Rattray, and P.J. Shaw Gene expression profiling in human neurodegenerative disease Nat Rev Neurol 8 2012 518 530
13. T. Wyss-Coray, and J. Rogers Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature Cold Spring Harb Perspect Med 2 2012 a006346
14. M. Michaud, L. Balardy, G. Moulis, C. Gaudin, C. Peyrot, and B. Vellas et al. Proinflammatory cytokines, aging, and age-related diseases J Am Med Dir Assoc 2013
15. C.A. Szekely, and P.P. Zandi Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence CNS Neurol Disord Drug Targets 9 2010 132 139
16. P.L. McGeer, S. Itagaki, H. Tago, and E.G. McGeer Occurrence of HLA-DR reactive microglia in Alzheimer's disease Ann NY Acad Sci 540 1988 319 323 (Pubitemid 19115338)
17. P.L. McGeer, H. Akiyama, S. Itagaki, and E.G. McGeer Activation of the classical complement pathway in brain tissue of Alzheimer patients Neurosci Lett 107 1989 341 346 (Pubitemid 20013261)
18. P.L. McGeer, E. McGeer, J. Rogers, and J. Sibley Anti-inflammatory drugs and Alzheimer disease Lancet 335 1990 1037 (Pubitemid 20148621)
19. C.M. Beard, E. Kokman, and L.T. Kurland Rheumatoid arthritis and susceptibility to Alzheimer's disease Lancet 337 1991 1426
20. J. Rogers, L.C. Kirby, S.R. Hempelman, D.L. Berry, P.L. McGeer, and A.W. Kaszniak et al. Clinical trial of indomethacin in Alzheimer's disease Neurology 43 1993 1609 1611 (Pubitemid 23230557)
21. J.C. Breitner, B.A. Gau, K.A. Welsh, B.L. Plassman, W.M. McDonald, and M.J. Helms et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study Neurology 44 1994 227 232 (Pubitemid 24070956)
22. J.B. Rich, D.X. Rasmusson, M.F. Folstein, K.A. Carson, C. Kawas, and J. Brandt Nonsteroidal anti-inflammatory drugs in Alzheimer's disease Neurology 45 1995 51 55
23. W.F. Stewart, C. Kawas, M. Corrada, and E.J. Metter Risk of Alzheimer's disease and duration of NSAID use Neurology 48 1997 626 632 (Pubitemid 27120096)
24. I. Mcdowell, G. Hill, and J. Lindsay et al. The Canadian Study of Health and Aging: risk factors for Alzheimer's disease in Canada Neurology 44 1994 2073 2080 (Pubitemid 24349508)
25. C.M. Beard, S.C. Waring, P.C. O'Brien, L.T. Kurland, and E. Kokmen Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Minnesota, 1980 through 1984 Mayo Clin Proc 73 1998 951 955
26. J.K. Choi, B.G. Jenkins, I. Carreras, S. Kaymakcalan, K. Cormier, and N.W. Kowall et al. Anti-inflammatory treatment in AD mice protects against neuronal pathology Exp Neurol 223 2010 377 384
27. N.H. Varvel, K. Bhaskar, M.Z. Kounnas, S.L. Wagner, Y. Yang, and B.T. Lamb et al. NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease J Clin Invest 119 2009 3692 3702
28. S. Sung, H. Yang, K. Uryu, E.B. Lee, L. Zhao, and D. Shineman et al. Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease Am J Pathol 165 2004 2197 2206 (Pubitemid 39578396)
29. G.P. Lim, F. Yang, T. Chu, P. Chen, W. Beech, and B. Teter et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease J Neurosci 20 2000 5709 5714 (Pubitemid 30636898)
30. G.P. Lim, F. Yang, T. Chu, E. Gahtan, O. Ubeda, and W. Beech et al. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice Neurobiol Aging 22 2001 983 991 (Pubitemid 34066567)
31. A.C. McKee, I. Carreras, L. Hossain, H. Ryu, W.L. Klein, and S. Oddo et al. Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice Brain Res 1207 2008 225 236
32. S.H. Choi, S. Aid, L. Caracciolo, S.S. Minami, T. Niikura, and Y. Matsuoka et al. Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease J Neurochem 124 2013 59 68
33. C.G. Lyketsos, J.C. Breitner, R.C. Green, B.K. Martin, C. Meinert, and S. Piantadosi et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial Neurology 68 2007 1800 1808 (Pubitemid 46791392)
34. B.K. Martin, C. Szekely, J. Brandt, S. Piantadosi, J.C. Breitner, and S. Craft et al. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib Arch Neurol 65 2008 896 905 (Pubitemid 352008472)
35. J.C. Breitner, B.K. Martin, and C.L. Meinert The suspension of treatments in ADAPT: concerns beyond the cardiovascular safety of celecoxib or naproxen PLoS Clin Trials 1 2006 e41
36. J.M. Leoutsakos, B.O. Muthen, J.C. Breitner, and C.G. Lyketsos Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's disease anti-inflammatory prevention trial Int J Geriatr Psychiatry 27 2012 364 374
37. J.C. Breitner, L.D. Baker, T.J. Montine, C.L. Meinert, C.G. Lyketsos, and K.H. Ashe et al. Extended results of the Alzheimer's disease anti-inflammatory prevention trial Alzheimers Dement 7 2011 402 411
38. K.R. Zahs, and K.H. Ashe 'Too much good news' - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? Trends Neurosci 33 2010 381 389
39. P. McGettigan, and D. Henry Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies PLoS Med 8 2011 e1001098
40. B. Liu, Y. Zhang, N. Zhu, H. Li, W. Luo, and Y. Zhou A vasoconstrictor role for cyclooxygenase-1-mediated prostacyclin synthesis in mouse renal arteries Am J Physiol Renal Physiol 2013
41. P. Vitale, S. Tacconelli, M.G. Perrone, P. Malerba, L. Simone, and A. Scilimati et al. Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors J Med Chem 56 2013 4277 4299
42. A.B. Edelman, J.T. Jensen, C. Doom, and J.D. Hennebold Impact of the prostaglandin synthase-2 inhibitor celecoxib on ovulation and luteal events in women Contraception 87 2013 352 357
43. J.P. Vogel, H.M. West, and T. Dowswell Titrated oral misoprostol for augmenting labour to improve maternal and neonatal outcomes Cochrane Database Syst Rev 9 2013 CD010648
44. M.R. Al-Kharusi, H.J. Smartt, A. Greenhough, T.J. Collard, E.D. Emery, and A.C. Williams et al. LGR5 promotes survival in human colorectal adenoma cells and is upregulated by PGE2: implications for targeting adenoma stem cells with NSAIDs Carcinogenesis 34 2013 1150 1157
45. Z.J. Dai, X.B. Ma, H.F. Kang, J. Gao, W.L. Min, and H.T. Guan et al. Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in vitro and in vivo Cancer Cell Int 12 2012 53
46. J. Shi, Q. Wang, J.U. Johansson, X. Liang, N.S. Woodling, and P. Priyam et al. Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease Ann Neurol 72 2012 788 798
47. C. Desbene, C. Malaplate-Armand, I. Youssef, P. Garcia, C. Stenger, and M. Sauvee et al. Critical role of cPLA2 in Abeta oligomer-induced neurodegeneration and memory deficit Neurobiol Aging 33 2012 1123 e17-29
48. C. Sagy-Bross, N. Hadad, and R. Levy Cytosolic phospholipase Aalpha upregulation mediates apoptotic neuronal death induced by aggregated amyloid-beta peptide Neurochem Int 63 2013 541 550
49. T.A. Rosenberger, N.E. Villacreses, M.A. Contreras, J.V. Bonventre, and S.I. Rapoport Brain lipid metabolism in the cPLA2 knockout mouse J Lipid Res 44 2003 109 117 (Pubitemid 36114776)
50. M. Reisenberg, P.K. Singh, G. Williams, and P. Doherty The diacylglycerol lipases: structure, regulation and roles in and beyond endocannabinoid signalling Philos Trans R Soc Lond B Biol Sci 367 2012 3264 3275
51. D.K. Nomura, B.E. Morrison, J.L. Blankman, J.Z. Long, S.G. Kinsey, and M.C. Marcondes et al. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation Science 334 2011 809 813
52. E.R. Greene, S. Huang, C.N. Serhan, and D. Panigrahy Regulation of inflammation in cancer by eicosanoids Prostaglandins Other Lipid Mediat 96 2011 27 36
53. A. Vegiopoulos, K. Muller-Decker, D. Strzoda, I. Schmitt, E. Chichelnitskiy, and A. Ostertag et al. Cyclooxygenase-2 controls energy homeostasis in mice by de novo recruitment of brown adipocytes Science 328 2010 1158 1161
54. J.E. Dinchuk, B.D. Car, R.J. Focht, J.J. Johnston, B.D. Jaffee, and M.B. Covington et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II Nature 378 1995 406 409
55. H. Lim, B.C. Paria, S.K. Das, J.E. Dinchuk, R. Langenbach, and J.M. Trzaskos et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice Cell 91 1997 197 208 (Pubitemid 27456387)
56. R.S. Bresalier, R.S. Sandler, H. Quan, J.A. Bolognese, B. Oxenius, and K. Horgan et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 352 2005 1092 1102 (Pubitemid 40365350)
57. S. Trelle, S. Reichenbach, S. Wandel, P. Hildebrand, B. Tschannen, and P.M. Villiger et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis BMJ 342 2011 c7086
58. J.J. Hoozemans, J.M. Rozemuller, E.S. van Haastert, R. Veerhuis, and P. Eikelenboom Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology Curr Pharm Des 14 2008 1419 1427 (Pubitemid 351982549)
59. Y. Kitamura, S. Shimohama, H. Koike, J. Kakimura, Y. Matsuoka, and Y. Nomura et al. Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains Biochem Biophys Res Commun 254 1999 582 586 (Pubitemid 29290509)
60. N.V. Chandrasekharan, H. Dai, K.L. Roos, N.K. Evanson, J. Tomsik, and T.S. Elton et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression PNAS 99 2002 13926 13931 (Pubitemid 35215482)
61. J.G. Cui, H. Kuroda, N.V. Chandrasekharan, R.P. Pelaez, D.L. Simmons, and N.G. Bazan et al. Cyclooxygenase-3 gene expression in Alzheimer hippocampus and in stressed human neural cells Neurochem Res 29 2004 1731 1737 (Pubitemid 39070064)
62. D.K. Dhull, D. Bhateja, R.K. Dhull, and S.S. Padi Differential role of cyclooxygenase isozymes on neuronal density in hippocampus CA1 region of intracerebroventricular streptozotocin treated rat brain J Chem Neuroanat 43 2012 48 51
63. N.V. Chandrasekharan, and D.L. Simmons The cyclooxygenases Genome Biol 5 2004 241
64. S. Aid, and F. Bosetti Gene expression of cyclooxygenase-1 and Ca(2+)-independent phospholipase A(2) is altered in rat hippocampus during normal aging Brain Res Bull 73 2007 108 113 (Pubitemid 46710255)
65. G.R. Weerasinghe, S.L. Coon, A.K. Bhattacharjee, G.J. Harry, and F. Bosetti Regional protein levels of cytosolic phospholipase A2 and cyclooxygenase-2 in Rhesus monkey brain as a function of age Brain Res Bull 69 2006 614 621 (Pubitemid 44250798)
66. W.J. Lukiw Gene expression profiling in fetal, aged, and Alzheimer hippocampus: a continuum of stress-related signaling Neurochem Res 29 2004 1287 1297 (Pubitemid 39023501)
67. M.T. Heneka, M. Sastre, L. Dumitrescu-Ozimek, A. Hanke, I. Dewachter, and C. Kuiperi et al. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice Brain 128 2005 1442 1453 (Pubitemid 40826196)
68. P.T. Jantzen, K.E. Connor, G. DiCarlo, G.L. Wenk, J.L. Wallace, and A.M. Rojiani et al. Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice J Neurosci 22 2002 2246 2254 (Pubitemid 35386524)
69. S.H. Choi, S. Aid, L. Caracciolo, S.S. Minami, T. Niikura, and Y. Matsuoka et al. Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease J Neurochem 124 2012 59 68
70. B.L. Wilkinson, P.E. Cramer, N.H. Varvel, E. Reed-Geaghan, Q. Jiang, and A. Szabo et al. Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer's disease Neurobiol Aging 33 2010 197 e21-32
71. S.H. Choi, and F. Bosetti Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid Aging (Albany, NY) 1 2009 234 244
72. M. Coma, L. Sereno, B. Da Rocha-Souto, T.C. Scotton, J. Espana, and M.B. Sanchez et al. Triflusal reduces dense-core plaque load, associated axonal alterations and inflammatory changes, and rescues cognition in a transgenic mouse model of Alzheimer's disease Neurobiol Dis 38 2010 482 491
73. T. Kukar, M.P. Murphy, J.L. Eriksen, S.A. Sagi, S. Weggen, and T.E. Smith et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production Nat Med 11 2005 545 550 (Pubitemid 40685978)
74. A.V. Yermakova, J. Rollins, L.M. Callahan, J. Rogers, and M.K. O'Banion Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons J Neuropathol Exp Neurol 58 1999 1135 1146 (Pubitemid 29519837)
75. J.J. Hoozemans, A.J. Rozemuller, I. Janssen, C.J. De Groot, R. Veerhuis, and P. Eikelenboom Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain Acta Neuropathol 101 2001 2 8 (Pubitemid 32124493)
76. J.L. Eriksen, S.A. Sagi, T.E. Smith, S. Weggen, P. Das, and D.C. McLendon et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo J Clin Invest 112 2003 440 449 (Pubitemid 38063773)
77. S. Weggen, J.L. Eriksen, S.A. Sagi, C.U. Pietrzik, V. Ozols, and A. Fauq et al. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity J Biol Chem 278 2003 31831 31837 (Pubitemid 37048365)
78. T. Borgegard, A. Jureus, F. Olsson, S. Rosqvist, A. Sabirsh, and D. Rotticci et al. First and second generation gamma-secretase modulators (GSMs) modulate amyloid-beta (Abeta) peptide production through different mechanisms J Biol Chem 287 2012 11810 11819
79. S. Weggen, J.L. Eriksen, P. Das, S.A. Sagi, R. Wang, and C.U. Pietrzik et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity Nature 414 2001 212 216 (Pubitemid 33051236)
80. T.L. Kukar, T.B. Ladd, M.A. Bann, P.C. Fraering, R. Narlawar, and G.M. Maharvi et al. Substrate-targeting gamma-secretase modulators Nature 453 2008 925 929
81. R.C. Green, L.S. Schneider, D.A. Amato, A.P. Beelen, G. Wilcock, and E.A. Swabb et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial JAMA 302 2009 2557 2564
82. G.K. Wilcock, S.E. Black, S.B. Hendrix, K.H. Zavitz, E.A. Swabb, and M.A. Laughlin Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial Lancet Neurol 7 2008 483 493
83. C.A. Szekely, R.C. Green, J.C. Breitner, T. Ostbye, A.S. Beiser, and M.M. Corrada et al. No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies Neurology 70 2008 2291 2298
84. B.S. Chan, J.A. Satriano, M. Pucci, and V.L. Schuster Mechanism of prostaglandin E2 transport across the plasma membrane of HeLa cells and Xenopus oocytes expressing the prostaglandin transporter "PGT" J Biol Chem 273 1998 6689 6697 (Pubitemid 28160327)
85. N. Kanai, R. Lu, J.A. Satriano, Y. Bao, A.W. Wolkoff, and V.L. Schuster Identification and characterization of a prostaglandin transporter Science 268 1995 866 869
86. R. Lu, N. Kanai, Y. Bao, and V.L. Schuster Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT) J Clin Invest 98 1996 1142 1149 (Pubitemid 26299927)
87. D. Milatovic, T.J. Montine, and M. Aschner Prostanoid signaling: dual role for prostaglandin E2 in neurotoxicity Neurotoxicology 32 2011 312 319
88. H.H. Chang, and E.J. Meuillet Identification and development of mPGES-1 inhibitors: where we are at? Future Med Chem 3 2011 1909 1934
89. D.D. Israel, and J.W. Regan EP(3) prostanoid receptor isoforms utilize distinct mechanisms to regulate ERK 1/2 activation Biochim Biophys Acta 1791 2009 238 245
90. G. Zhen, Y.T. Kim, R.C. Li, J. Yocum, N. Kapoor, and J. Langer et al. PGE2 EP1 receptor exacerbated neurotoxicity in a mouse model of cerebral ischemia and Alzheimer's disease Neurobiol Aging 33 2012 2215 2219
91. C.D. Keene, R.C. Chang, A.H. Lopez-Yglesias, B.R. Shalloway, I. Sokal, and X. Li et al. Suppressed accumulation of cerebral amyloid {beta} peptides in aged transgenic Alzheimer's disease mice by transplantation with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow Am J Pathol 177 2010 346 354
92. X. Liang, Q. Wang, T. Hand, L. Wu, R.M. Breyer, and T.J. Montine et al. Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease J Neurosci 25 2005 10180 10187 (Pubitemid 41636214)
93. T. Hoshino, T. Namba, M. Takehara, N. Murao, T. Matsushima, and Y. Sugimoto et al. Improvement of cognitive function in Alzheimer's disease model mice by genetic and pharmacological inhibition of the EP(4) receptor J Neurochem 120 2012 795 805
94. T. Hoshino, T. Namba, M. Takehara, T. Nakaya, Y. Sugimoto, and W. Araki et al. Prostaglandin E2 stimulates the production of amyloid-beta peptides through internalization of the EP4 receptor J Biol Chem 284 2009 18493 18502
95. C.D. Keene, R. Chang, C. Stephen, M. Nivison, S.E. Nutt, and A. Look et al. Protection of hippocampal neurogenesis from toll-like receptor 4-dependent innate immune activation by ablation of prostaglandin E2 receptor subtype EP1 or EP2 Am J Pathol 174 2009 2300 2309
96. M. Shimamura, P. Zhou, B. Casolla, L. Qian, C. Capone, and H. Kurinami et al. Prostaglandin E2 type 1 receptors contribute to neuronal apoptosis after transient forebrain ischemia J Cereb Blood Flow Metab 33 2013 1207 1214
97. T. Abe, A. Kunz, M. Shimamura, P. Zhou, J. Anrather, and C. Iadecola The neuroprotective effect of prostaglandin E2 EP1 receptor inhibition has a wide therapeutic window, is sustained in time and is not sexually dimorphic J Cereb Blood Flow Metab 29 2009 66 72
98. X. Li, S.E. Rose, K.S. Montine, C.D. Keene, and T.J. Montine Antagonism of neuronal prostaglandin E(2) receptor subtype 1 mitigates amyloid beta neurotoxicity in vitro J Neuroimmune Pharmacol 8 2013 87 93
99. C.A. Rohrbeck, and C.T. Twentyman Multimodal assessment of impulsiveness in abusing, neglecting, and nonmaltreating mothers and their preschool children J Consult Clin Psychol 54 1986 231 236 (Pubitemid 17106022)
100. P.J. Cimino, Y. Yang, X. Li, J.F. Hemingway, M.K. Cherne, and S.B. Khademi et al. Ablation of the microglial protein DOCK2 reduces amyloid burden in a mouse model of Alzheimer's disease Exp Mol Pathol 94 2013 366 371
101. A. Savonenko, P. Munoz, T. Melnikova, Q. Wang, X. Liang, and R.M. Breyer et al. Impaired cognition, sensorimotor gating, and hippocampal long-term depression in mice lacking the prostaglandin E2 EP2 receptor Exp Neurol 217 2009 63 73
102. J. Shi, J. Johansson, N.S. Woodling, Q. Wang, T.J. Montine, and K. Andreasson The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity J Immunol 184 2010 7207 7218
103. A.M. Pooler, A.A. Arjona, R.K. Lee, and R.J. Wurtman Prostaglandin E2 regulates amyloid precursor protein expression via the EP2 receptor in cultured rat microglia Neurosci Lett 362 2004 127 130 (Pubitemid 38759083)
104. M. Ahmad, A.S. Ahmad, H. Zhuang, T. Maruyama, S. Narumiya, and S. Dore Stimulation of prostaglandin E2-EP3 receptors exacerbates stroke and excitotoxic injury J Neuroimmunol 184 2007 172 179 (Pubitemid 46365999)
105. G. O'Callaghan, A. Ryan, P. Neary, C. O'Mahony, F. Shanahan, and A. Houston Targeting the EP1 receptor reduces Fas ligand expression and increases the antitumor immune response in an in vivo model of colon cancer Int J Cancer 133 2013 825 834
106. M. Ikeda, M. Kawatani, T. Maruyama, and H. Ishihama Prostaglandin facilitates afferent nerve activity via EP1 receptors during urinary bladder inflammation in rats Biomed Res 27 2006 49 54
107. A. Shahbazian, A. Heinemann, B.A. Peskar, and P. Holzer Differential peristaltic motor effects of prostanoid (DP, EP, IP, TP) and leukotriene receptor agonists in the guinea-pig isolated small intestine Br J Pharmacol 137 2002 1047 1054 (Pubitemid 35440745)
108. M.A. Birrell, S.A. Maher, J. Buckley, N. Dale, S. Bonvini, and K. Raemdonck et al. Selectivity profiling of the novel EP2 receptor antagonist, PF-04418948, in functional bioassay systems: atypical affinity at the guinea pig EP2 receptor Br J Pharmacol 168 2013 129 138
109. H. Aso, S. Ito, A. Mori, N. Suganuma, M. Morioka, and N. Takahara et al. Differential regulation of airway smooth muscle cell migration by E-prostanoid receptor subtypes Am J Respir Cell Mol Biol 48 2013 322 329
110. J. Buckley, M.A. Birrell, S.A. Maher, A.T. Nials, D.L. Clarke, and M.G. Belvisi EP4 receptor as a new target for bronchodilator therapy Thorax 66 2011 1029 1035
111. M.J. Jugus, J.P. Jaworski, P.B. Patra, J. Jin, D.M. Morrow, and N.J. Laping et al. Dual modulation of urinary bladder activity and urine flow by prostanoid EP3 receptors in the conscious rat Br J Pharmacol 158 2009 372 381
112. Y. Ikeda-Matsuo, H. Tanji, S. Narumiya, and Y. Sasaki Inhibition of prostaglandin E2 EP3 receptors improves stroke injury via anti-inflammatory and anti-apoptotic mechanisms J Neuroimmunol 238 2011 34 43
113. G.H. Hung, R.L. Jones, F.F. Lam, K.M. Chan, H. Hidaka, and M. Suzuki et al. Investigation of the pronounced synergism between prostaglandin E2 and other constrictor agents on rat femoral artery Prostaglandins Leukot Essent Fatty Acids 74 2006 401 415 (Pubitemid 43816853)
114. D. Longrois, I. Gomez, N. Foudi, G. Topal, M. Dhaouadi, and L. Kotelevets et al. Prostaglandin E(2) induced contraction of human intercostal arteries is mediated by the EP(3) receptor Eur J Pharmacol 681 2012 55 59
115. I. Mohri, K. Kadoyama, T. Kanekiyo, Y. Sato, K. Kagitani-Shimono, and Y. Saito et al. Hematopoietic prostaglandin D synthase and DP1 receptor are selectively upregulated in microglia and astrocytes within senile plaques from human patients and in a mouse model of Alzheimer disease J Neuropathol Exp Neurol 66 2007 469 480 (Pubitemid 46869689)
116. G. Ciabattoni, E. Porreca, C. Di Febbo, A. Di Iorio, R. Paganelli, and T. Bucciarelli et al. Determinants of platelet activation in Alzheimer's disease Neurobiol Aging 28 2007 336 342 (Pubitemid 46177381)
117. Z. Amtul, M. Uhrig, L. Wang, R.F. Rozmahel, and K. Beyreuther Detrimental effects of arachidonic acid and its metabolites in cellular and mouse models of Alzheimer's disease: structural insight Neurobiol Aging 33 2012 831 e21-31
118. P.T. Wong, P.L. McGeer, and E.G. McGeer Decreased prostaglandin synthesis in postmortem cerebral cortex from patients with Alzheimer's disease Neurochem Int 21 1992 197 202
119. T. Kanekiyo, T. Ban, K. Aritake, Z.L. Huang, W.M. Qu, and I. Okazaki et al. Lipocalin-type prostaglandin D synthase/beta-trace is a major amyloid beta-chaperone in human cerebrospinal fluid PNAS 104 2007 6412 6417 (Pubitemid 47186108)
120. M.A. Lovell, B.C. Lynn, S. Xiong, J.F. Quinn, J. Kaye, and W.R. Markesbery An aberrant protein complex in CSF as a biomarker of Alzheimer disease Neurology 70 2008 2212 2218
121. C. Bate, S. Kempster, and A. Williams Prostaglandin D2 mediates neuronal damage by amyloid-beta or prions which activates microglial cells Neuropharmacology 50 2006 229 237 (Pubitemid 43100008)
122. K.M. Kim, B.H. Jung, K.J. Paeng, I. Kim, and B.C. Chung Increased urinary F(2)-isoprostanes levels in the patients with Alzheimer's disease Brain Res Bull 64 2004 47 51 (Pubitemid 38953468)
123. L. Yuan, and P. Lester Oxidative stress and age-related neurodegeneration 2006 CRC Press Boca Raton, FL
124. J.H. Soper, S. Sugiyama, K. Herbst-Robinson, M.J. James, X. Wang, and J.Q. Trojanowski et al. Brain-penetrant tetrahydronaphthalene thromboxane A2-prostanoid (TP) receptor antagonists as prototype therapeutics for Alzheimer's disease ACS Chem Neurosci 3 2012 928 940
125. D.W. Shineman, B. Zhang, S.N. Leight, D. Pratico, and V.M. Lee Thromboxane receptor activation mediates isoprostane-induced increases in amyloid pathology in Tg2576 mice J Neurosci 28 2008 4785 4794
126. H. Soininen, C. West, J. Robbins, and L. Niculescu Long-term efficacy and safety of celecoxib in Alzheimer's disease Dement Geriatr Cogn Disord 23 2007 8 21 (Pubitemid 46005786)
127. P. Pasqualetti, C. Bonomini, G. Dal Forno, L. Paulon, E. Sinforiani, and C. Marra et al. A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease Aging Clin Exp Res 21 2009 102 110
128. P.S. Aisen, K.L. Davis, J.D. Berg, K. Schafer, K. Campbell, and R.G. Thomas et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study Neurology 54 2000 588 593 (Pubitemid 30082922)
129. S.A. Reines, G.A. Block, J.C. Morris, G. Liu, M.L. Nessly, and C.R. Lines et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study Neurology 62 2004 66 71 (Pubitemid 38082872)
130. L.J. Thal, S.H. Ferris, L. Kirby, G.A. Block, C.R. Lines, and E. Yuen et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment Neuropsychopharmacology 30 2005 1204 1215 (Pubitemid 40720980)
131. P.S. Aisen, K.A. Schafer, M. Grundman, E. Pfeiffer, M. Sano, and K.L. Davis et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial JAMA 289 2003 2819 2826 (Pubitemid 37430117)
132. T. Gomez-Isla, R. Blesa, M. Boada, J. Clarimon, T. Del Ser, and G. Domenech et al. A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study Alzheimer Dis Assoc Disord 22 2008 21 29 (Pubitemid 351651394)